Table II.

SNPs in the AKR1C3 gene associated with bladder cancer risk, adjusted for gender, age, region and smoking status (1150 cases and 1149 controls)

AKR1C3 SNP	Genotype	Cases		Controls		OR	95% CI	P value
		n	%	n	%
rs1937845 (GoldenGate assay)	AA	355	33	300	29	1.00	Reference
−488A>G	AG	541	50	518	50	0.86	0.70–1.06	0.15
Highly correlated with rs12529	GG	189	17	215	21	0.74	0.57–0.96	0.02
Per allele risk						0.86	0.75–0.98	0.02
rs3763676 (GoldenGate assay)	AA	443	41	471	46	1.00	Reference
−137A>G	AG	498	46	433	42	1.28	1.05–1.55	0.01
Highly correlated with rs1937843	GG	145	13	128	12	1.19	0.89–1.58	0.23
Per allele risk						1.14	1.00–1.30	0.05
rs4881400 (iPLEX assay)	TT	558	63	523	60	1.00	Reference
IVS5-256T>G	GT	294	33	294	34	0.92	0.75–1.14	0.45
	GG	32	4	56	6	0.53	0.33–0.85	0.01
Per allele risk						0.83	0.70–0.98	0.03
rs12775701 (iPLEX assay)	GG	230	26	263	30	1.00	Reference
IVS7+336A>G	GA	437	49	413	47	1.22	0.96–1.54	0.10
	AA	221	25	198	23	1.34	1.02–1.76	0.04
Per allele risk						1.16	1.01–1.33	0.04
rs4641368 (iPLEX assay)	CC	663	75	610	70	1.00	Reference
IVS8+584C>T	CT	212	24	239	27	0.82	0.66–1.03	0.09
	TT	11	1	24	3	0.42	0.20–0.91	0.03
Per allele risk						0.78	0.64–0.95	0.01

This table shows findings for a subset of the 24 SNPs evaluated in the AKR1C3 gene significantly associated with bladder cancer risk. See supplementary Table 1 (available at Carcinogenesis Online) for findings on all SNPs evaluated; GoldenGate genotyping assays were performed among 1086 cases and 1033 controls. iPLEX genotyping assays were performed on 946 cases and 912 controls. See Materials and Methods and Table I for details.

Note: Differences between cell counts in table and total number of cases and controls are due to missing genotype data.